Entrada Therapeutics Net Worth
Entrada Therapeutics Net Worth Breakdown | TRDA |
Entrada Therapeutics Net Worth Analysis
Entrada Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Entrada Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Entrada Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Entrada Therapeutics' net worth analysis. One common approach is to calculate Entrada Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Entrada Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Entrada Therapeutics' net worth. This approach calculates the present value of Entrada Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Entrada Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Entrada Therapeutics' net worth. This involves comparing Entrada Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Entrada Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Entrada Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Entrada Therapeutics' net worth research are outlined below:
| Entrada Therapeutics generated a negative expected return over the last 90 days | |
| Entrada Therapeutics has high historical volatility and very poor performance | |
| Entrada Therapeutics currently holds about 244.25 M in cash with (41.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.81. | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Entrada Therapeutics CFO sells 19,035 in stock - Investing.com |
Entrada Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Entrada Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Entrada Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Entrada Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Entrada Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Entrada Therapeutics backward and forwards among themselves. Entrada Therapeutics' institutional investor refers to the entity that pools money to purchase Entrada Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 573.9 K | State Street Corp | 2024-12-31 | 505 K | Northern Trust Corp | 2024-12-31 | 318.2 K | Goldman Sachs Group Inc | 2024-12-31 | 285.3 K | Arrowstreet Capital Limited Partnership | 2024-12-31 | 222.5 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 217 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 212.7 K | Charles Schwab Investment Management Inc | 2024-12-31 | 197.1 K | Renaissance Technologies Corp | 2024-12-31 | 166.2 K | Baker Bros Advisors Lp | 2024-12-31 | 4.9 M | 5am Venture Management, Llc | 2024-12-31 | 4.4 M |
Follow Entrada Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 394.37 M.Market Cap |
|
Project Entrada Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.13 | |
| Return On Capital Employed | 0.10 | 0.10 | |
| Return On Assets | 0.12 | 0.13 | |
| Return On Equity | 0.15 | 0.09 |
When accessing Entrada Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Entrada Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Entrada Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Entrada Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Entrada Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Entrada Therapeutics' management manipulating its earnings.
Evaluate Entrada Therapeutics' management efficiency
Entrada Therapeutics has return on total asset (ROA) of 0.059 % which means that it generated a profit of $0.059 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1956 %, meaning that it created $0.1956 on every $100 dollars invested by stockholders. Entrada Therapeutics' management efficiency ratios could be used to measure how well Entrada Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Entrada Therapeutics' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Capital Employed is expected to grow to 0.10, whereas Return On Equity is forecasted to decline to 0.09. At present, Entrada Therapeutics' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.13, whereas Total Assets are forecasted to decline to about 296.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.49 | 12.07 | |
| Tangible Book Value Per Share | 11.49 | 12.07 | |
| Enterprise Value Over EBITDA | 12.83 | 13.47 | |
| Price Book Value Ratio | 1.50 | 1.58 | |
| Enterprise Value Multiple | 12.83 | 13.47 | |
| Price Fair Value | 1.50 | 1.58 | |
| Enterprise Value | 603 M | 585 M |
Management at Entrada Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 0.145 | Revenue | Quarterly Revenue Growth (0.11) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entrada Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entrada Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Entrada Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Entrada Therapeutics Corporate Filings
F4 | 19th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Entrada Therapeutics Earnings per Share Projection vs Actual
Entrada Therapeutics Corporate Management
| Kory CPA | CFO Treasurer | Profile | |
| Kerry MS | Senior People | Profile | |
| Jared JD | General Counsel | Profile | |
| Nathan Dowden | Chief Officer | Profile | |
| Karla MacDonald | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.69 | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.